Alternative splice variants of DCLK1 mark cancer stem cells, promote self-renewal and drug-resistance, and can be targeted to inhibit tumorigenesis in kidney cancer
Yang Ge, Nathaniel Weygant, Dongfeng Qu, Randal May, William L. Berry, Jiannan Yao, Parthasarathy Chandrakesan, Wei Zheng, Lichao Zhao, Karena L. Zhao, Michael Drake, Kenneth J Vega, Michael S. Bronze, James J. Tomasek, Guangyu An, Courtney W. Houchen
Research output: Contribution to journal › Article › peer-review
Dive into the research topics of 'Alternative splice variants of DCLK1 mark cancer stem cells, promote self-renewal and drug-resistance, and can be targeted to inhibit tumorigenesis in kidney cancer'. Together they form a unique fingerprint.